XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.3
Collaborative Arrangements - AstraZeneca PLC - Narrative (Details) - Lynparza - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2022
Licenses and Other      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Finite-lived intangible assets $ 1,300,000,000    
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Probable contingent payments     $ 600,000,000
Liabilities     $ 600,000,000
Eligible future contingent sales-based milestone payments (up to) 2,100,000,000    
Regulatory milestone payments 245,000,000 $ 105,000,000  
Eligible future contingent regulatory milestone payments (up to) $ 0